We also investigated the potential toxicologic impact of GS-PPMO treatment and knockdown of GYS1 mRNA to assess the therapeutic index associated with administering this particular type of antisense oligonucleotide for Pompe disease. This evidence concerns the gene GYS1 and Glycogen storage disease due to acid maltase deficiency.